Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
39.36
+0.85 (2.22%)
Oct 20, 2026, 11:33 AM EDT - Market open
Genmab Employees
Genmab had 3,119 employees as of June 30, 2026. The number of employees increased by 480 or 18.19% compared to the same quarter last year.
Employees
3,119
Change
480
Growth
18.19%
Revenue / Employee
$1,324,463
Profits / Employee
$252,645
Market Cap
23.31B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 3,119 | 480 | 18.19% |
| Mar 31, 2026 | 3,088 | 450 | 17.06% |
| Dec 31, 2025 | 2,973 | 339 | 12.87% |
| Sep 30, 2025 | 2,681 | 46 | 1.75% |
| Jun 30, 2025 | 2,639 | 113 | 4.47% |
| Mar 31, 2025 | 2,638 | 352 | 15.40% |
| Dec 31, 2024 | 2,634 | 430 | 19.51% |
| Sep 30, 2024 | 2,635 | 503 | 23.59% |
| Jun 30, 2024 | 2,526 | 511 | 25.36% |
| Mar 31, 2024 | 2,286 | 440 | 23.84% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Sep 30, 2023 | 2,132 | 572 | 36.67% |
| Jun 30, 2023 | 2,015 | 570 | 39.45% |
| Mar 31, 2023 | 1,846 | 537 | 41.02% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Sep 30, 2022 | 1,560 | 424 | 37.32% |
| Jun 30, 2022 | 1,445 | 416 | 40.43% |
| Mar 31, 2022 | 1,309 | 438 | 50.29% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Revolution Medicines | 883 |
GMAB News
- 3 hours ago - Genmab price target raised to $42 from $35 at Morgan Stanley - TheFly
- 7 days ago - Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year - Nasdaq
- 7 days ago - Genmab reports Q3 net sales of Darzalex $4.24B - TheFly
- 7 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 - GlobeNewsWire
- 9 days ago - Genmab (CPH:GEN) -- Pipeline Progress and Market Resilience | Baird Funds Q3 2026 - GuruFocus
- 12 days ago - Genmab To Issue Restricted Stock Units To Board Members As Renumeration - Nasdaq
- 12 days ago - Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - GlobeNewsWire
- 13 days ago - Genmab price target raised to $45 from $40 at Truist - TheFly